Delcath Systems Inc (DCTH)

0.13
0.02 11.00
NASDAQ : Health Care
Prev Close 0.15
Open 0.15
Day Low/High 0.13 / 0.15
52 Wk Low/High 3.35 / 10.88
Volume 53.09M
Avg Volume 104.66M
Exchange NASDAQ
Shares Outstanding 499.03M
Market Cap 84.84M
EPS -10.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Delcath Issues Letter To Stockholders

Delcath Announces 2016 Financial Results

Delcath Announces Special Protocol Assessment Agreement With FDA For Pivotal Trial With Melphalan/HDS In Intrahepatic Cholangiocarcinoma

Company Plans to file 2016 Fourth Quarter and Year End Financial Results by March 30, 2017

Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies

Single-Center Retrospective Data Also Demonstrate Therapy Extends Progression-Free Survival by 9 Months

Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential Of Delcath Investigational PHP Therapy

Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000...

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution...

3 Breakout Stocks Under $10 to Trade Now

3 Breakout Stocks Under $10 to Trade Now

These under-$10 stocks are within range of triggering breakout trades.

Delcath Systems (DCTH) Weak On High Volume

Delcath Systems (DCTH) Weak On High Volume

Trade-Ideas LLC identified Delcath Systems (DCTH) as a weak on high relative volume candidate

5 Active Under-$10 Stocks to Buy Now

5 Active Under-$10 Stocks to Buy Now

When a stock makes a large move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Northwest Bio's German Smokescreen Obscures DCVax Problems

Northwest Bio's German Smokescreen Obscures DCVax Problems

Northwest Bio received good news from Germany in February but didn't tell investors until Monday.

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Greater Fools Love Delcath, Zalicus On Orphan Drug Derpitude

Greater Fools Love Delcath, Zalicus On Orphan Drug Derpitude

Momentum traders don't understand FDA regulations.

First Week Of DCTH March 2014 Options Trading

First Week Of DCTH March 2014 Options Trading

Investors in Delcath Systems Inc. saw new options begin trading this week, for the March 2014 expiration.

Ask SUT

This week, David Peltier answers questions about two model portfolio names and two other specific low-dollar stocks.

Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors Of Upcoming Deadlines In Shareholder Litigation Involving Delcath Systems, Inc., Amyris, Inc., Nam Tai Electronics, Inc. And Accretive Health, Inc.

Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors Of Upcoming Deadlines In Shareholder Litigation Involving Delcath Systems, Inc., Amyris, Inc., Nam Tai Electronics, Inc. And Accretive Health, Inc.

Holzer Holzer & Fistel LLC reminds investors of upcoming deadlines for applications to serve as lead plaintiff in securities class action lawsuits against Delcath Systems, Inc.

Law Offices Of Todd M. Garber Announces Class Action Lawsuit Against Delcath Systems, Inc.

Law Offices Of Todd M. Garber Announces Class Action Lawsuit Against Delcath Systems, Inc.

The Law Offices of Todd M. Garber announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class (the “Class”) comprising all ...

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

2013 FDA Drug Approval Calendar

2013 FDA Drug Approval Calendar

An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.

Leaders of <I>TheStreet's</I> Drug Approval Contest

Leaders of TheStreet's Drug Approval Contest

This group of contestants have nearly perfect records picking FDA and European drug approvals.

Stock Futures Eye Rebound on ECB Stimulus, U.S. Data

Stock Futures Eye Rebound on ECB Stimulus, U.S. Data

Stock futures are looking to rebound from losses in the prior session.

Aveo, Delcath FDA Panel Live Blog

Aveo, Delcath FDA Panel Live Blog

Join TheStreet's Adam Feuerstein as he live blogs FDA advisory panels for Aveo Oncology and Delcath Systems

FDA Tells Delcath No Approval Without New Clinical Trial

FDA Tells Delcath No Approval Without New Clinical Trial

Delcath's liver-tumor device uses a filter that FDA says does not work.

Prepping for Aveo, Delcath FDA Panels

Prepping for Aveo, Delcath FDA Panels

It's a big week for Aveo and Delcath, starting Tuesday with FDA reviews of their respective cancer products.

Biotech's Next Big Thing: Aveo

Biotech's Next Big Thing: Aveo

TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.